EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire

2025/10/23

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025

Company to host conference call and webcast on Thursday, November 6^th at 8:30am EST

AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6^th, 2025.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date: Thursday, November 6^th

Time: 8:30 am EST

Domestic: 1-800-274-8461

International: 1-203-518-9814

Passcode: EDAP

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1738018&tp_key=c91765d4a0

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One^® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577306835"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577306835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577306835?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577306835","market":"hk","top_or_hot":-1,"title":"EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025","media":"GlobeNewswire","content":"<html><body><p>EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025</p> <p><em>Company to host conference call and webcast on Thursday, November 6</em><sup><em>th</em></sup><em> at 8:30am EST</em></p> <p>AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6<sup>th</sup>, 2025. </p> <p>An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. </p> <p><strong>Call Details:</strong></p> <p>Date:                Thursday, November 6<sup>th</sup> </p> <p>Time:                8:30 am EST</p> <p>Domestic:          1-800-274-8461</p> <p>International:      1-203-518-9814</p> <p>Passcode:          EDAP</p> <p>Webcast:           https://viavid.webcasts.com/starthere.jsp?ei=1738018&amp;tp_key=c91765d4a0 </p> <p><strong>About EDAP TMS SA </strong></p> <p>A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One<sup>®</sup> in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/</p> <p><strong>Company Contact</strong><br/>Blandine Confort<br/>Investor Relations / Legal Affairs<br/>EDAP TMS SA<br/>+33 4 72 15 31 50<br/>bconfort@edap-tms.com</p> <p><strong>Investor Contact</strong><br/>John Fraunces<br/>LifeSci Advisors, LLC<br/>(917) 355-2395<br/>jfraunces@lifesciadvisors.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/OGFkM2U3MzItODRjNS00NzIzLTk3ZGUtMjkyMmNlZDA3ZjNhLTEwMzg1NTEtMjAyNS0xMC0yMy1lbg==/tiny/EDAP-TMS-S-A-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-10-23 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025</p> <p><em>Company to host conference call and webcast on Thursday, November 6</em><sup><em>th</em></sup><em> at 8:30am EST</em></p> <p>AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6<sup>th</sup>, 2025. </p> <p>An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. </p> <p><strong>Call Details:</strong></p> <p>Date:                Thursday, November 6<sup>th</sup> </p> <p>Time:                8:30 am EST</p> <p>Domestic:          1-800-274-8461</p> <p>International:      1-203-518-9814</p> <p>Passcode:          EDAP</p> <p>Webcast:           https://viavid.webcasts.com/starthere.jsp?ei=1738018&amp;tp_key=c91765d4a0 </p> <p><strong>About EDAP TMS SA </strong></p> <p>A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One<sup>®</sup> in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/</p> <p><strong>Company Contact</strong><br/>Blandine Confort<br/>Investor Relations / Legal Affairs<br/>EDAP TMS SA<br/>+33 4 72 15 31 50<br/>bconfort@edap-tms.com</p> <p><strong>Investor Contact</strong><br/>John Fraunces<br/>LifeSci Advisors, LLC<br/>(917) 355-2395<br/>jfraunces@lifesciadvisors.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/OGFkM2U3MzItODRjNS00NzIzLTk3ZGUtMjkyMmNlZDA3ZjNhLTEwMzg1NTEtMjAyNS0xMC0yMy1lbg==/tiny/EDAP-TMS-S-A-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3171869/9622/en/EDAP-to-Announce-Third-Quarter-2025-Financial-Results-on-November-6-2025.html","article_id":"2577306835","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577306835","pubTimestamp":1761217200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","EDAP":"Edap Tms SA"},"translate_title":"EDAP将于2025年11月6日公布2025年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDAP":1.5},"content_text":"EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (「the Company」), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6th, 2025.  An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.  Call Details: Date:                Thursday, November 6th  Time:                8:30 am EST Domestic:          1-800-274-8461 International:      1-203-518-9814 Passcode:          EDAP Webcast:           https://viavid.webcasts.com/starthere.jsp?ei=1738018&tp_key=c91765d4a0  About EDAP TMS SA  A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/ Company ContactBlandine ConfortInvestor Relations / Legal AffairsEDAP TMS SA+33 4 72 15 31 50bconfort@edap-tms.com Investor ContactJohn FrauncesLifeSci Advisors, LLC(917) 355-2395jfraunces@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}